drugset

drugset / Trial / NCT02321592

GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02321592 ↗

Phase 2 Completed 23 enrolled University of Cologne Affimed GmbH · collab The Leukemia and Lymphoma Society · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study is designed * to demonstrate efficacy of AFM13 with an optimized treatment schedule * to decide whether AFM13 warrants further investigation in a phase III clinical trial

Timeline

Start: 2015-05
Primary completion: 2019-11
Completion: 2020-07

Publications

Sasse S, Brockelmann PJ, Momotow J, Plutschow A, Huttmann A, Basara N, Koenecke C, Martin S, Bentz M, Grosse-Thie C, Thorspecken S, de Wit M, Kobe C, Dietlein M, Tresckow BV, Fuchs M, Borchmann P, Engert A. AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial. Leuk Lymphoma. 2022 Aug;63(8):1871-1878. doi: 10.1080/10428194.2022.2095623. Epub 2022 Jul 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	ACIMTAMIG	Protein / enzyme biologic	—	Other

Indications